New insights into the treatment of pulmonary fibrosis

Bibliography

• GREEN FHY: Overview of pulmonary fibrosis. Chest (2002) 122:334S–339S.
   Google Scholar
• COULTAS DB, ZUM WALT RE, BLACK WC, SOBONYA RE: The epidemiology of interstitial lung diseases. Am. Respic Crit. Care Merl (1994) 150:967–972.
   PubMed Web of Science ®Google Scholar
• NICOD LP: Recognition and treatment of idiopathic pulmonary fibrosis. Drugs (1998) 55:555–562.
   PubMed Web of Science ®Google Scholar
• CHAN ED, WORTHEN GS, AUGUSTIN A, LAPADAT R, RICHES DWH: Inflammation in the pathogenesis of interstitial lung disease. In: Interstitial Lung Disease (3rd edn). Schwartz MI, King TE Jr (Eds), BC Decker, Hamilton, London, UK (1998):135–164.
   Google Scholar
• SEMENZATO G, GURRIERI C, ADAMI F, AGOSTINI C: Sarcoidosis. In: Textbook of Respiratory Cell and Molecular Biology Wardlaw AJ, Hamid Q (Eds), Martin Dunitz, London, UK (2002):133–146.
   Google Scholar
• KIRK JME, HEARD BE, KERR I, TURNER-WARWICK M, LAURENT GJ: Quantitation of Types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis. Coll Rel. Res. (1984) 4:169–182.
   PubMedGoogle Scholar
• SEYER JM, KANG AH, RODNAN G: Investigation of Type I and Type III collagens of the lung in progressive systemic sclerosis. Arthritic Rheum. (1981) 24:625–631.
   PubMed Web of Science ®Google Scholar
• KATZENSTEIN A-L, MYERS JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. .1 Respir. Grit. Care Med. (1998) 157:1301–1315.
   Google Scholar
• TRAVIS WD, KING TE Jr, BATEMAN ED et al.: American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. j Respic Grit. Care Med. (2002) 165:277–304.
   PubMedGoogle Scholar
• JOHNSTON CJ, WILLIAMS JP, OKUNIEFF P, FINKELSTEIN JN: Radiation-induced pulmonary fibrosis: examination of chemokine and chemokine receptor families. RadiaL Res. (2002) 157:256–265.
   PubMed Web of Science ®Google Scholar
• FLEISCHMAN RW, BAKER JR, THOMPSON GR et al.: Bleomycin-induced interstitial pneumonia in dogs. Thorax (1971) 26:675–688.
   PubMed Web of Science ®Google Scholar
• GOULD VE, MILLER J: Sclerosing alveolitisinduced by cyclophosphamide. Ukrastructural observations on alveolar injury and repair. Am. Pathol (1975) 81:513–530.
   Google Scholar
• VON WICHERT P, MORGENROTH K: Comparison between pathological and biochemical investigations on an experimental model of fibrosing alveolitis. Respiration (1976) 33:36–46.
   PubMed Web of Science ®Google Scholar
• BUTLER C: Pulmonary interstitial fibrosis from paraquat in the hamster. Arch. Pathol (1975) 99:503–507.
   PubMedGoogle Scholar
• DERKS CM, JACOBOVITZ-DERKS D: Embolic pneumopathy induced by oleic acid. A systematic morphologic study. Am. .1 Pathol (1977) 87:143–158.
   Google Scholar
• DAMIANO VV, CHERIAN PV, FRANKEL FR et al.: Intraluminal fibrosis induced unilaterally by lobar instillation of CdC12 into the rat lung. Am. .1 Pathol (1990) 137:883–894.
   Google Scholar
• HALME J, UITTO J, KAHANPAA K, KARHUNEN P, LINDY S: Protocollagen proline hydroxylase activity in experimental pulmonary fibrosis of rats. .1 Lab. Clin. Med. (1970) 75:535–541.
   PubMed Web of Science ®Google Scholar
• GLASSROTH JL, BERNARDO J, LUCEY EC, CENTER DM, JUNG- LEGG YJ, SNIDER GL: Interstitial pulmonary fibrosis induced in hamsters by intratracheally administered chrysotile asbestos. Histology, lung mechanics, and inflammatory events. Am. Rev Respir. Dis. (1984) 130:242–248.
   PubMed Web of Science ®Google Scholar
• MAQUART FX, BELLON G, CHAQOUR B et al: In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. .1. Clin. Invest. (1993) 92:2368–2376.
   PubMed Web of Science ®Google Scholar
• PANOS RJ: Potential therapies for interstitial lung disease. In: Interstitial Lung Disease (3rd edn). Schwartz MI, King TE Jr (Eds), BC Decker, Hamilton, London, UK (1998):265–277.
   Google Scholar
• •A thorough review of contemporary approaches to prevent pulmonary fibrosis or augment reparative processes.
   Google Scholar
• KING TE Jr, COSTABEL U, CORDIERJF et al.: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am. .1 Respic Crit. Care Med. (2000) 161:646–664.
   Google Scholar
• AGGARWAL BB, SAMANTA A, FELDMANN M: TNF-a. In: Cytokine Reference. Oppenheim JJ, Feldmann M (Eds in Chief), Acad. Press, San Diego, USA (1991):413–434.
   Google Scholar
• PERISTERIS P, CLARK BD, GATTI Set al.: N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell. Immunol. (1992) 140:390–399.
   Google Scholar
• GOSSET P, WALLAERT B, TUNNEL AB, FOURNEAU C: Thiol regulation of the production of TNF-a, IL-6 and IL-8 by human alveolar macrophages. Eui: Respic (1999) 14:98–105.
   PubMed Web of Science ®Google Scholar
• CHAN SH, PERUSSIA B, GUPTA JW et al.: Induction of interferon y production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. I Exp. Med. (1991) 173:869–879.
   PubMed Web of Science ®Google Scholar
• WU CY, DEMEURE C, KINIWA M, GATELY M, DELESPESSE G: IL-12 induces the production of IFN-y by neonatal human CD4 T cells." Immunol (1993) 151:1938–1949.
   PubMed Web of Science ®Google Scholar
• GHARAEE-KERMANI M, DENHOLM EM, PHAN SH: Costimulation of fibroblast collagen and transforming growth factor 131 gene expression by monocyte chemoattractant protein-1 via specific receptors.' Biol. Chem. (1996) 271:17779–17784.
   Web of Science ®Google Scholar
• SELMAN M, KING TE, PARDO A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Merl (2001) 134:136–151.
   PubMed Web of Science ®Google Scholar
• GAHL WA, BRANTLY M, TROENDLEJ et al.: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Ma Genet. Metab. (2002) 76:234–242.
   PubMed Web of Science ®Google Scholar
• NAGAI S, HAMADA K, SHIGEMATSU M,TANIYAMA M, YAMAUCHI S, IZUMI T: Open-label compassionate use 1-year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. (2002) 41:1118–1123.
   PubMed Web of Science ®Google Scholar
• LASKY JA, BRODY AR: Interstitial fibrosis and growth factors. Environ. Health Perspect. (2000) 108(Suppl.):751–762.
   Google Scholar
• PENTTINEN RP, KOBAYASHI S, BORNSTEIN P: Transforming growth factor 13 increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. USA (1988) 85:1105–1108.
   PubMed Web of Science ®Google Scholar
• JIMENEZ SA, VARGA J, OLSEN A et al: Functional analysis of human al (I) procollagen gene promoter. Differential activity in collagen-producing and -non-producing cells and response to transforming growth factor Pl. 'Bid Chem. (1994) 269:12684–12691.
   Google Scholar
• INAGAKI Y, TRUTER S, RAMIREZ F: Transforming growth factor-I3 stimulates a2 (I) collagen gene expression through a cis-acting element that contains an Sp 1-bindingsite. Biol. Chem. (1994) 269:14828–14834.
   Web of Science ®Google Scholar
• OVERALL CM, WRANA JL, SODEKJ: Transforming growth factor-I3 regulation of collagenase, 72 kDa-progelatinase, TIMP and PAT-1 expression in rat bone cell populations and human fibroblasts. Connect. Tissue Res (1989) 20:289–294.
   PubMed Web of Science ®Google Scholar
• WRIGHT JK, CAWSTON TE, HAZLEMAN BL: Transforming growth factor 13 stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim. Biophys. Acta (1991) 1094:207–210.
   PubMedGoogle Scholar
• KOTHAPALLI R, BUYUKSAL I, WU SQ, CHEGINI N, TABIBZADEH S: Detection of ebaf, a novel human gene of the transforming growth factor 13 superfamily: association of gene expression with endometrial bleeding. j. Clin. Invest. (1997) 99:2342–2350.
   PubMed Web of Science ®Google Scholar
• GROTENDORST GR, OKOCHE H, HAYASHI N: A novel transforming growth factor 13 response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. (1996) 7:469–480.
   PubMedGoogle Scholar
• AGGARWAL BB, SINGH S, LAPUSHIN R, TOTPAL K: Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett. (1995) 364:5–8.
   PubMed Web of Science ®Google Scholar
• FREIBERG RA, SPENCER DM, CHOATE KA et al.: Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts.' Invest. Dermatol (1997) 108:215–219.
   PubMed Web of Science ®Google Scholar
• YUROVSKY VV: Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am. I Respic Cell. Ma Blot (2003) 28:225–231.
   PubMed Web of Science ®Google Scholar
• SIEGBAHN A, HAMMACHER A, VVESTERMARK B, HELDIN CH: Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. Clin. Invest. (1990) 85:916–920.
   Google Scholar
• PIERCE GE VAN DE BERG J, RUDOLPH R, TARPLEY J, MUSTOE TA: Platelet-derived growth factor-BB and transforming growth factor 131 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. Am. J. Pathol (1991) 138:629–646.
   PubMed Web of Science ®Google Scholar
• HOWARD EW, BENTON R, AHERN-MOORE J, TOMASEK JJ: Cellular contraction of collagen lattices is inhibited by non-enzymatic glycation. Exp. Cell Res (1996) 228:132–137.
   PubMed Web of Science ®Google Scholar
• SAJITHLAL GB, CHITHRA P, CHANDRAKASAN G: Advanced glycation end products induce crosslinking of collagen in vitro. Biochim. Biophys. Acta (1998) 1407:215–224.
   PubMed Web of Science ®Google Scholar